MedTrace Logo

Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial

NCT04721301 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-10-17

No results posted yet for this study

Summary

The study will be conducted in compliance with Good Clinical Practices (ICH-GCP) and the Declaration of Helsinki, and in accordance with applicable legal and regulatory requirements, including archiving of essential documents.

Conditions

  • Colorectal Cancer Metastatic
  • Pancreatic Cancer Metastatic

Interventions

COMBINATION_PRODUCT

Nivolumab plus Ipilimumab plus Maraviroc

In the single treatment arm, all patients receive Nivolumab, Ipilimumab and Maraviroc

Sponsors & Collaborators

  • German Cancer Research Center

    collaborator OTHER

  • University Hospital Heidelberg

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-15
Primary Completion
2023-03-15
Completion
2023-03-15

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04721301 on ClinicalTrials.gov